ECI Pharmaceuticals, LLC is a privately-held U.S. manufacturer of generic prescription pharmaceuticals. ECI performs pharmaceutical research and development, as well as, it markets/distributes a broad range of generic prescription products in many therapeutic categories and dosage forms.


Throughout the United States, ECI’s label is recognized by:

  • Retail Pharmacy Chains
  • Mail Order Pharmacies
  • Pharmacy Benefit Managers
  • Managed Care Facilities
  • Group Purchasing Org.
  • Wholesalers
  • Distributors
  • Hospitals


Products are marketed in a variety of dosage forms including:

  • Tablets
  • Capsules
  • Creams
  • Lotions
  • Liquids
  • Powders


ECI has Abbreviated New Drug Applications (ANDA’s) approved by the Food and Drug Administration (FDA) and has several products in its pipeline that include ANDA’s and NDA’s.



ECI Pharmaceuticals LLC. is a privately-held corporation.  We are an own label Distributor that performs pharmaceutical research and development, as well as, marketing and distribution in the U.S. market. ECI markets a broad range of Generic and DESI prescription products in many therapeutic categories and dosage forms.

Throughout the United States the ECI label is recognized by:

  • Retail Pharmacy Chains
  • Mail Order Pharmacies
  • Pharmacy Benefit Managers
  • Managed Care Facilities
  • Group Purchasing Organizations
  • Wholesalers
  • Distributors

We currently market 34 products in a variety of dosage forms including:  tablets, capsules, creams, lotions, liquids, and powders. We also offer Sales and Marketing support to Trinity Pharmaceuticals, BioRamo, and Noble Pharmaceuticals.

ECI, with company offices in Ft Lauderdale, has 26 approved Abbreviated New Drug Applications (ANDA’s) approved by the Food and Drug Administration (FDA).  We also have over 30 products in our pipeline that include ANDAs and NDAs. Moreover, we look to expand to the global market in late 2018.

Executive Management Team

The quality of our organization is reflected in the standards and attention to detail we set for ourselves. It’s our responsibility.

John H. Copanos
CEO and Founder
Mr. Copanos, third generation pharmaceutical manufacturer, began his career in Baltimore, Maryland, working at Enzytek, Ltd., an API manufacturer of Beta-lactam antibiotics. He then joined Consolidated Pharmaceuticals Inc., eventually ascending to Director of Sales and Marketing. In 2000, Mr. Copanos founded Kirk Pharmaceuticals, Inc., an OTC solid and liquid-dose manufacturing firm. In 2004 Mr. Copanos founded his second company, Andapharm LLC, a solid-dose specialty manufacturer focusing on controlled substances and HRT products. In 2006, the two companies – with combined annual sales of approximately $18 million – were sold to a publicly traded company.

Ellen Gettenberg
VP, Commercial Operations
Ms. Gettenberg began her career in the generic pharmaceutical industry over twenty years ago. Most recently she had served as Director of Marketing at two leading generic pharmaceutical companies where she earned a solid track record with many successful U.S. generic launches. She currently serves as Vice President of Commercial Operations at ECI Pharmaceuticals LLC, where she is responsible for strategic pipeline and portfolio planning, product launches, market analysis and market share growth. Ms. Gettenberg holds a Bachelor of Arts in Math and Economics from Boston University, Boston, MA.

Gregory Jean-Noel, M.D.
Clinical Medical Director
Dr. Jean-Noel is a medical doctor with a strong research background. He recently earned a Masters in Business Administration with an emphasis in Strategic Management from Davenport University in Grand Rapids, Michigan. He served as a Research Assistant at Xavier University of Louisiana and Downstate Medical Center, Brooklyn, NY, and performed research for Pfizer’s Global Research and Development division. Dr. Jean-Noel earned his Doctor in Medicine degree from Belize Medical College in 2010.

Abul K. Bhuiyan
CSO/VP Operations
Mr. Bhuiyan is a results oriented leader with 30+ years of professional experience in the formulation of liquid, ointment, encapsulated, and tablet drug products and over 20 years’ experience in the preparation of FDA submissions for new product development with leading pharmaceutical companies. He is a vital member of ECI’s executive team with comprehensive and diverse experience across pharmaceutical manufacturing.

He is an expert in all aspects of FDA generic drug regulations including cGMP’s and has maintained a strong and positive relationship with the FDA throughout his career.

Dusty Snoeberg
Acting VP Quality
Dusty has more than 24 years combined FDA and Industry experience regarding interpretation and implementation of FDA regulatory requirements. Her focus has been specifically the implementation of quality systems (CGMP’s) as it pertains to 21 CFR 210, 211. She holds a Bachelor’s Degree in General Science and has completed master level courses in Pharmaceutical Manufacturing at the University of Cincinnati Pharmacy College.

Robert Sharpnack
VP of Compliance

Since January, 2017 to present, Bob has served as VP of Compliance for ECI Pharmaceuticals. Bob retired from the U.S. Food & Drug Administration (FDA) in 2004 after spending 32 years in various positions including; district drug specialist, supervisory investigator, compliance officer where his last position was a regional drug specialist.

Bob has been consulting full time since retiring from FDA, primarily helping both sterile and non-sterile pharmaceutical manufacturing industry and also auditing clinical research establishments. While working as a consultant, Bob helped secure (8) successful pre-approval inspections (PAI’s). Bob also is a certified quality auditor (CQA) with the American Society of Quality (ASQ).